Nanostics Inc., a precision health company specializing in diagnostic tests through its ClarityDX® platform, has partnered with OncoHelix, a leader in precision diagnostics. Together, they will offer ClarityDX Prostate® to…
ExThera Medical has successfully completed the Phase I OSCAR I Study at OU Health Stephenson Cancer Center, affiliated with the University of Oklahoma. The OSCAR I Study is a prospective,…
C2N Diagnostics, a global leader in Alzheimer’s diagnostics with its Precivity blood tests, plans to develop a fully automated and standardized high-resolution LC-MS platform. This technology will allow local clinical…
Almirall, S.A. (ALM), a global leader in medical dermatology, will participate in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam from September 25 to…
Topline Results from TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan The TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) against investigator’s choice chemotherapy has reported that while the treatment met…
Alzprotect, a French biopharma company, has successfully completed the open-label extension (OLE) phase of its Phase 2a trial for AZP2006 (ezeprogind®) in treating Progressive Supranuclear Palsy (PSP). Results from the…
MedTech Innovator (MTI), the world’s largest accelerator for medical technology companies, announced that its BioTools Innovator (BTI) program has been chosen as the Enabling Technologies Hub for the next generation…
Novotech, an international contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Managing Director of the Asia Pacific (APAC) region, effective September 1, 2024. This strategic…
RevBio, Inc. has secured a $2.4 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke (NINDS), part of the NIH. The two-year grant will support…
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine…
Genentech, part of the Roche Group, announced that the U.S. FDA has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).…
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotech firm specializing in developing treatments for rare and serious diseases, has announced the pricing of its public offering. The company will sell 10,666,600…